Teva Pharmaceutical Industries Ltd. (Nasdaq:TEVA; TASE:TEVA) today announced that the US District Court for the Southern District of New York has set a trial date of September 7, 2011 for the company’s ongoing patent infringement litigation against Momenta Pharmaceuticals, Inc., Sandoz Inc., and Mylan Pharmaceuticals, Inc. and Natco Pharma Ltd. regarding their generic versions of multiple sclerosis treatment Copaxone.

Teva’s chief legal officer Richard Egosi said, “Teva remains committed to vigorously defending its intellectual property rights against infringement. We are very pleased to have a trial date as we are confident we will prevail in this litigation."

Teva's share price has fallen 23% since last May on fears that generic Copaxone will get the green light. The multiple sclerosis treatment had sales of $3.3 billion in 2010.

Teva's share price was down 1.31% at NIS 180.60 on the TASE this afternoon. The share price closed at $50.10 on Nasdaq yesterday, giving a market cap of $45 billion.

Published by Globes, Israel business news - www.globes-online.com - on March 1, 2011

© Copyright of Globes Publisher Itonut (1983) Ltd. 2011